$28.02−1.04 (−3.58%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Ionis Pharmaceuticals (IONS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~3.9%/yr (FY21→FY25), net margin −40.4%. Worth your attention in FY25: Share count (+13.5%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲33.8%
943.7
FY21→FY25CAGR +3.9%/yr
Net income ($M)▲16.0%
−381.4
one-off year: see footnoteCAGR —
Free cash flow ($M)▲41.4%
−320.0
FY21→FY25CAGR —
Diluted EPS▲21.7%
−2.38
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+13.5%
141.0mn → 160.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$51.4M
steady at 5.5% of revenue (+13.6% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-40¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 98.7% → 98.3%. Net margin -40.4% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 960,092.0 | 943,711.0 | 705,138.0 | 787,647.0 | 587,367.0 | 810,456.0 | ▲33.8% | +3.9% |
Cost of revenue | 17,001.0 | 15,909.0 | 11,215.0 | 9,133.0 | 14,116.0 | 10,842.0 | ▲41.9% | +10.1% |
Gross profit | 943,091.0 | 927,802.0 | 693,923.0 | 778,514.0 | 573,251.0 | 799,614.0 | ▲33.7% | +3.8% |
Research & development | 922,804.0 | 915,619.0 | 901,530.0 | 899,625.0 | 833,147.0 | 643,453.0 | ▲1.6% | +9.2% |
Selling, general & admin | 585,163.0 | 393,867.0 | 267,474.0 | 232,619.0 | 150,295.0 | 186,347.0 | ▲47.3% | +20.6% |
Total operating expenses | 1,507,967.0 | 1,309,486.0 | 1,169,004.0 | 1,132,244.0 | 983,442.0 | 829,800.0 | ▲12.0% | +12.1% |
Operating incomefeeds ROC rank | −564,876.0 | −381,684.0 | −475,081.0 | −353,730.0 | −410,191.0 | −30,186.0 | ▲19.7% | — |
Other income, net | 21,155.0 | 2,083.0 | 15,013.0 | 19,765.0 | 152,206.0 | 1,038.0 | — | — |
Pretax income | −543,721.0 | −379,601.0 | −460,068.0 | −333,965.0 | −257,985.0 | −29,148.0 | ▲17.5% | — |
Income tax | 2,818.0 | 1,786.0 | −6,171.0 | 32,321.0 | 11,737.0 | −551.0 | — | −46.6% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −546,539.0 | −381,387.0 | −453,897.0 | −366,286.0 | −269,722.0 | −28,597.0 | ▲16.0% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.26 | −2.38 | −3.04 | −2.56 | −1.90 | −0.20 | ▲21.7% | — |
Diluted shares (mn) | 166.21 | 160.01 | 149.51 | 143.19 | 141.85 | 141.02 | ▲7.0% | +3.2% |
| Margins | ||||||||
Gross margin95th pct in Healthcare | 98.2% | 98.3% | 98.4% | 98.8% | 97.6% | 98.7% | ▼0.1pp | −0.3pp |
Operating margin | −58.8% | −40.4% | −67.4% | −44.9% | −69.8% | −3.7% | ▲26.9pp | −36.7pp |
Net margin14th pct in Healthcare | −56.9% | −40.4% | −64.4% | −46.5% | −45.9% | −3.5% | ▲24.0pp | −36.9pp |
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was −10% vs a −0% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 13 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Ionis Pharmaceuticals' revenue last fiscal year?
Ionis Pharmaceuticals reported revenue of $943.7M in fiscal 2025, up 33.8% from fiscal 2024.
What was Ionis Pharmaceuticals' net income?
Ionis Pharmaceuticals reported net income of −$381.4M in fiscal 2025, a net margin of −40.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

